[go: up one dir, main page]

PE20120515A1 - Formulaciones de deferiprona - Google Patents

Formulaciones de deferiprona

Info

Publication number
PE20120515A1
PE20120515A1 PE2011001408A PE2011001408A PE20120515A1 PE 20120515 A1 PE20120515 A1 PE 20120515A1 PE 2011001408 A PE2011001408 A PE 2011001408A PE 2011001408 A PE2011001408 A PE 2011001408A PE 20120515 A1 PE20120515 A1 PE 20120515A1
Authority
PE
Peru
Prior art keywords
deferiprone
formulations
compound
eye
iron
Prior art date
Application number
PE2011001408A
Other languages
English (en)
Inventor
Michael Spino
Joshua Lawrence Dunaief
Original Assignee
Michael Spino
Joshua Lawrence Dunaief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Spino, Joshua Lawrence Dunaief filed Critical Michael Spino
Publication of PE20120515A1 publication Critical patent/PE20120515A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA AL COMPUESTO DEFERIPRONA Y A UNA COMPOSICION FARMACEUTICA ORAL O TOPICA QUE LA COMPRENDE, DONDE DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE LESIONES OCULARES ASOCIADAS CON EL HIERRO Y/O UN MAL MANEJO DEL METABOLISMO DEL HIERRO EN EL OJO
PE2011001408A 2009-01-26 2009-11-12 Formulaciones de deferiprona PE20120515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26

Publications (1)

Publication Number Publication Date
PE20120515A1 true PE20120515A1 (es) 2012-05-20

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001408A PE20120515A1 (es) 2009-01-26 2009-11-12 Formulaciones de deferiprona

Country Status (24)

Country Link
US (1) US20130023569A1 (es)
EP (1) EP2389179A4 (es)
JP (1) JP5604631B2 (es)
KR (1) KR20120078667A (es)
CN (1) CN102348456A (es)
AP (1) AP2011005843A0 (es)
AU (1) AU2009338093B2 (es)
BR (1) BRPI0920492A2 (es)
CA (1) CA2750599A1 (es)
CL (1) CL2011001812A1 (es)
CR (1) CR20110456A (es)
EA (1) EA201170970A1 (es)
IL (1) IL214291A (es)
MA (1) MA33090B1 (es)
MX (1) MX2011007947A (es)
MY (1) MY161269A (es)
NI (1) NI201100148A (es)
NZ (1) NZ594728A (es)
PE (1) PE20120515A1 (es)
SG (1) SG173145A1 (es)
TN (1) TN2011000366A1 (es)
UA (1) UA103366C2 (es)
WO (1) WO2010083582A1 (es)
ZA (1) ZA201105514B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11517540B2 (en) 2015-01-09 2022-12-06 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
US10940116B2 (en) 2017-10-25 2021-03-09 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
WO2004071425A2 (en) * 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
BRPI0710737A2 (pt) 2006-04-14 2011-05-10 Prana Biotechnology Ltd uso de compostos pb-10 33 éteis para o tratamento de degeneraÇço macular relacionada À idade (amd), assim como referidos compostos
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
CL2011001812A1 (es) 2012-02-03
KR20120078667A (ko) 2012-07-10
EA201170970A1 (ru) 2012-03-30
US20130023569A1 (en) 2013-01-24
EP2389179A4 (en) 2012-08-29
IL214291A0 (en) 2011-09-27
ZA201105514B (en) 2012-10-31
CN102348456A (zh) 2012-02-08
MX2011007947A (es) 2011-12-14
CA2750599A1 (en) 2010-07-29
IL214291A (en) 2015-03-31
CR20110456A (es) 2012-05-31
AU2009338093A1 (en) 2011-09-08
WO2010083582A1 (en) 2010-07-29
NZ594728A (en) 2013-03-28
JP5604631B2 (ja) 2014-10-08
EP2389179A1 (en) 2011-11-30
AU2009338093B2 (en) 2014-08-28
AP2011005843A0 (en) 2011-08-31
JP2012515725A (ja) 2012-07-12
UA103366C2 (ru) 2013-10-10
MA33090B1 (fr) 2012-03-01
BRPI0920492A2 (pt) 2019-07-09
SG173145A1 (en) 2011-08-29
NI201100148A (es) 2012-03-06

Similar Documents

Publication Publication Date Title
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
GB0920703D0 (en) Compositions containing satiogens and methods of use
EA201100978A1 (ru) Схема приема агониста рецептора s1p
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
NZ717728A (en) Stable formulations of a hyaluronan-degrading enzyme
GT201200276A (es) Combinaciones de compuestos activos
BR112012022774A2 (pt) Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
MX2010014041A (es) Una forma cristalina de posaconazol.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CR20150174A (es) Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
EA201270581A1 (ru) Фармацевтические композиции севеламера
PE20121538A1 (es) Combinaciones terapeuticas de teobromina y una antihistamina
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
CR20110010A (es) Formulaciones que tienen una compatibilidad mejorada con sustratos no tejidos
PE20120515A1 (es) Formulaciones de deferiprona
DOP2015000089A (es) Composición de difenidol de liberación prolongada
UA108993C2 (en) MEDICINAL COMBINATION WITH THEOBROMINE AND ITS APPLICATION IN Cough

Legal Events

Date Code Title Description
FC Refusal